# Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

> **NCT03717155** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 43 (actual)

## Conditions studied

- Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Cetuximab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03717155
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-30
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-05-27
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03717155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03717155, "Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03717155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*